Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effect of Losmapimod on blood vessels in
patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease,
it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks
and stroke). The investigators believe that this is a result of inflammation within the body,
which damages the lining (endothelium) and walls of blood vessels. These changes can promote
the development of fatty deposits within the walls of arteries (atherosclerosis) which can
rupture and block arteries causing damage.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborators:
GlaxoSmithKline Royal Brompton & Harefield NHS Foundation Trust Technology Strategy Board, United Kingdom University of Cambridge